Business Context and Reporting Period
Journey Medical Corporation filed a Form 8-K reporting that it entered into a Credit Agreement on December 27, 2023. The agreement provides a senior secured term loan facility with SWK Funding LLC and other lenders. The filing was signed January 2, 2024, and includes a related press release issued that day.
Key Financial Terms and Metrics
- Facility size: Up to $20 million.
- Initial borrowing: $15 million drawn on December 27, 2023; the remaining $5 million may be drawn upon request within 12 months after the closing date.
- Maturity: December 27, 2027, unless terminated earlier under the agreement.
- Interest rate: Three-month term SOFR, subject to a 5% floor, plus 7.75%. The filing does not provide the resulting effective rate at closing.
- Default rate: The loan rate plus 3%, subject to applicable legal limits.
- Amortization: Beginning February 2026, quarterly principal payments equal to 7.5% of funded term loans are required. If trailing-twelve-month revenue exceeds $70 million as of December 31, 2025, amortization is deferred until February 2027 and then increases to quarterly payments equal to 15% of funded term loans.
- Fees: A $200,000 origination fee was paid at closing. Upon full repayment, an exit fee equal to 5% of the original principal amount is due.
- Prepayment: Prepayment premiums are 2% of prepaid principal plus specified interest through the first anniversary if prepaid during the first year, 1% if prepaid during the second year, and 0% thereafter.
- Collateral: Obligations are secured by all or substantially all assets of the Company and its subsidiaries.
- Liquidity and financial covenants: The Company must comply with minimum liquidity and minimum total revenue covenants, with cure rights as specified in the Credit Agreement. The filing does not provide the covenant thresholds.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative revenue, profit, cash flow, margin, debt, or liquidity data. The material event is the creation of a new secured term loan facility and the initial $15 million borrowing.
Outlook, Risks, Contingencies, and Unusual Items
- The Company is subject to affirmative and negative covenants covering, among other matters, financial reporting, insurance, indebtedness, liens, investments, mergers, asset dispositions, dividends, and other distributions.
- Events of default include payment and covenant defaults, inaccurate representations, cross-defaults, bankruptcy or insolvency events, invalidity of guarantees or security interests, change of control, and certain litigation, judgment, ERISA, and forfeiture events.
- An event of default could accelerate the Company’s obligations under the Credit Agreement.
- The filing creates additional interest, amortization, prepayment, exit-fee, collateral, and covenant obligations. It does not provide management guidance on revenue, profitability, cash flow, or the intended use of proceeds.
- The full Credit Agreement was to be filed with a subsequent periodic report; the filing’s summary is qualified by reference to that agreement.
Important Facts for Investors to Verify
- Review the complete Credit Agreement, including the precise minimum liquidity and minimum revenue covenant thresholds and cure provisions.
- Confirm the current outstanding balance, any additional draw under the $5 million commitment, and the applicable SOFR rate.
- Assess the Company’s ability to satisfy quarterly interest, future principal amortization, and the 5% exit fee.
- Evaluate the consequences of the broad security package and the restrictions on additional debt, liens, investments, distributions, and asset sales.
- Monitor whether trailing-twelve-month revenue exceeds $70 million as of December 31, 2025, which would alter the amortization schedule.